Fig 5 - by Mary J. Obayemi (11813022)

Reduced ADAMTS-12 expression levels decrease EVT invasion. by Alexander G. Beristain (225001)

Higher baseline PV rates decrease the need for interneuron specialization. by Joram Keijser (12475353)

Early increase and later decrease in GSK-3β activity. by Arie J. Hoogendijk (353624)

Brain uptake of [¹⁴C]docosahexaenoic acid (DHA) in 2-, 8-, 12-, and 24-month-old mice. by Takuro Iwao (14636741)

Subjects:

Decrease of actin velocity when passing confined TCR clusters. by Cheng-han Yu (244912)

Cellular uptake of [¹⁴C]docosahexaenoic acid (DHA) by RBECs transfected with MFSD2A siRNA. by Takuro Iwao (14636741)

Subjects:

Fig 5 - by Jacob C. Jentzer (4746999)

Antibody and antigen responses after treatment with nMAb vs placebo, day 1-90 (pooled nMAb treatments). by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to Ensovibep vs placebo day 1–90. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to Lufotrelvir vs placebo day 1–90. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Amubarvimab/ Romlusevimab. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Tixagevimab/ Cilgavimab. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Bamlanivimab. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Sotrovimab. by Elizabeth S. Munroe (21568166)

Subjects:

Study Flow Diagram. by Elizabeth S. Munroe (21568166)

Subjects:

Ageing results in an abrupt decrease in overall neurogenesis in the mouse DG. by Joana Gil-Mohapel (462002)

“…(C) An estimation of overall neurogenesis based on the total number of BrdU-positive cells that survived the 42-day period multiplied by the proportion of BrdU-positive cells that acquired a mature neuronal phenotype indicates an age-induced significant and abrupt decrease in the overall number of new neurons. *** <i>p</i> < 0.001 between 1.5 and 3 months and between 3 and 6 months. …”

Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for nMAbs, among patients alive and with day 90 antibody and antigen measures (Sensitivity Analysis). by Elizabeth S. Munroe (21568166)

Subjects:

Decrease of full-length tRNAs under oxidative stress. by Jiayong Zhong (757895)

“…The data are shown as the mean ± SD. (C) Decreased tRNA levels following 30 min of OS, measured by next-generation sequencing. …”

Long-term anti-nucleocapsid response by baseline patient characteristics. by Elizabeth S. Munroe (21568166)

Subjects: